Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study

Sumio Hoka, Junichi Yoshitake, Kenjiro Dan, Yutaka Goto, Natsuo Honda, Tohru Morioka, Takesuke Muteki, Yoshiro Okuda, Akio Shigematsu, Mayumi Takasaki, Tadahide Totoki, Nozomu Yoshimura

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

The purpose of this multi-center study was to evaluate the efficacy and safety of prostaglandin E1 (PGE1) administration in achieving deliberate hypotension and in treating intraoperative hypertension for patients with a history of hypertension and ischemic heart disease. PGE1 (0.08 μg·kg-1·min-1) decreased systolic blood pressure from 125±29 to 106±22 mmHg (mean±SD) in the deliberate hypotension group (n=158) and from 155±34 to 125±32 mmHg in the antihypertension group (n=55). The heart rate significantly increased from 80±15 to 85±18 beatsomin-1 in the deliberate hypotension group, but was not significantly altered in the antihypertension group. The time required to obtain the desired level of blood pressure was approximately 20 min in the deliberate hypotension group. When the infusion was stopped, blood pressure returned approximately to the preinfusion level within about 20 min. No rebound hypertension was observed. PGE1 significantly increased the urine flow in patients who had a low urine flow before PGE1 infusion. Thirteen out of 213 patients (5.6%) had side effects such as excessive hypotension (1%), phlebitis (3%), and unexpected tachycardia (1 %), which were alleviated gradually after discontinuation of PGEI infusion. No dysarrhythmia and further ST segment changes in the electrocardiograms were observed. These findings suggest that PGE1 can be safely used to control arterial blood pressure during surgery in patients having preoperative hypertension and ischemic heart disease.

元の言語英語
ページ(範囲)173-183
ページ数11
ジャーナルJournal of Anesthesia
7
発行部数2
DOI
出版物ステータス出版済み - 4 1 1993

Fingerprint

Alprostadil
Hypotension
Myocardial Ischemia
Blood Pressure
Hypertension
Urine
Phlebitis
Tachycardia
Arterial Pressure
Electrocardiography
Heart Rate
Safety

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

これを引用

Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study. / Hoka, Sumio; Yoshitake, Junichi; Dan, Kenjiro; Goto, Yutaka; Honda, Natsuo; Morioka, Tohru; Muteki, Takesuke; Okuda, Yoshiro; Shigematsu, Akio; Takasaki, Mayumi; Totoki, Tadahide; Yoshimura, Nozomu.

:: Journal of Anesthesia, 巻 7, 番号 2, 01.04.1993, p. 173-183.

研究成果: ジャーナルへの寄稿記事

Hoka, S, Yoshitake, J, Dan, K, Goto, Y, Honda, N, Morioka, T, Muteki, T, Okuda, Y, Shigematsu, A, Takasaki, M, Totoki, T & Yoshimura, N 1993, 'Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study', Journal of Anesthesia, 巻. 7, 番号 2, pp. 173-183. https://doi.org/10.1007/s0054030070173
Hoka, Sumio ; Yoshitake, Junichi ; Dan, Kenjiro ; Goto, Yutaka ; Honda, Natsuo ; Morioka, Tohru ; Muteki, Takesuke ; Okuda, Yoshiro ; Shigematsu, Akio ; Takasaki, Mayumi ; Totoki, Tadahide ; Yoshimura, Nozomu. / Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study. :: Journal of Anesthesia. 1993 ; 巻 7, 番号 2. pp. 173-183.
@article{71f1f4adc5b24cdca46bd71ac62c1cb8,
title = "Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study",
abstract = "The purpose of this multi-center study was to evaluate the efficacy and safety of prostaglandin E1 (PGE1) administration in achieving deliberate hypotension and in treating intraoperative hypertension for patients with a history of hypertension and ischemic heart disease. PGE1 (0.08 μg·kg-1·min-1) decreased systolic blood pressure from 125±29 to 106±22 mmHg (mean±SD) in the deliberate hypotension group (n=158) and from 155±34 to 125±32 mmHg in the antihypertension group (n=55). The heart rate significantly increased from 80±15 to 85±18 beatsomin-1 in the deliberate hypotension group, but was not significantly altered in the antihypertension group. The time required to obtain the desired level of blood pressure was approximately 20 min in the deliberate hypotension group. When the infusion was stopped, blood pressure returned approximately to the preinfusion level within about 20 min. No rebound hypertension was observed. PGE1 significantly increased the urine flow in patients who had a low urine flow before PGE1 infusion. Thirteen out of 213 patients (5.6{\%}) had side effects such as excessive hypotension (1{\%}), phlebitis (3{\%}), and unexpected tachycardia (1 {\%}), which were alleviated gradually after discontinuation of PGEI infusion. No dysarrhythmia and further ST segment changes in the electrocardiograms were observed. These findings suggest that PGE1 can be safely used to control arterial blood pressure during surgery in patients having preoperative hypertension and ischemic heart disease.",
author = "Sumio Hoka and Junichi Yoshitake and Kenjiro Dan and Yutaka Goto and Natsuo Honda and Tohru Morioka and Takesuke Muteki and Yoshiro Okuda and Akio Shigematsu and Mayumi Takasaki and Tadahide Totoki and Nozomu Yoshimura",
year = "1993",
month = "4",
day = "1",
doi = "10.1007/s0054030070173",
language = "English",
volume = "7",
pages = "173--183",
journal = "Journal of Anesthesia",
issn = "0913-8668",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease - A multi-center study

AU - Hoka, Sumio

AU - Yoshitake, Junichi

AU - Dan, Kenjiro

AU - Goto, Yutaka

AU - Honda, Natsuo

AU - Morioka, Tohru

AU - Muteki, Takesuke

AU - Okuda, Yoshiro

AU - Shigematsu, Akio

AU - Takasaki, Mayumi

AU - Totoki, Tadahide

AU - Yoshimura, Nozomu

PY - 1993/4/1

Y1 - 1993/4/1

N2 - The purpose of this multi-center study was to evaluate the efficacy and safety of prostaglandin E1 (PGE1) administration in achieving deliberate hypotension and in treating intraoperative hypertension for patients with a history of hypertension and ischemic heart disease. PGE1 (0.08 μg·kg-1·min-1) decreased systolic blood pressure from 125±29 to 106±22 mmHg (mean±SD) in the deliberate hypotension group (n=158) and from 155±34 to 125±32 mmHg in the antihypertension group (n=55). The heart rate significantly increased from 80±15 to 85±18 beatsomin-1 in the deliberate hypotension group, but was not significantly altered in the antihypertension group. The time required to obtain the desired level of blood pressure was approximately 20 min in the deliberate hypotension group. When the infusion was stopped, blood pressure returned approximately to the preinfusion level within about 20 min. No rebound hypertension was observed. PGE1 significantly increased the urine flow in patients who had a low urine flow before PGE1 infusion. Thirteen out of 213 patients (5.6%) had side effects such as excessive hypotension (1%), phlebitis (3%), and unexpected tachycardia (1 %), which were alleviated gradually after discontinuation of PGEI infusion. No dysarrhythmia and further ST segment changes in the electrocardiograms were observed. These findings suggest that PGE1 can be safely used to control arterial blood pressure during surgery in patients having preoperative hypertension and ischemic heart disease.

AB - The purpose of this multi-center study was to evaluate the efficacy and safety of prostaglandin E1 (PGE1) administration in achieving deliberate hypotension and in treating intraoperative hypertension for patients with a history of hypertension and ischemic heart disease. PGE1 (0.08 μg·kg-1·min-1) decreased systolic blood pressure from 125±29 to 106±22 mmHg (mean±SD) in the deliberate hypotension group (n=158) and from 155±34 to 125±32 mmHg in the antihypertension group (n=55). The heart rate significantly increased from 80±15 to 85±18 beatsomin-1 in the deliberate hypotension group, but was not significantly altered in the antihypertension group. The time required to obtain the desired level of blood pressure was approximately 20 min in the deliberate hypotension group. When the infusion was stopped, blood pressure returned approximately to the preinfusion level within about 20 min. No rebound hypertension was observed. PGE1 significantly increased the urine flow in patients who had a low urine flow before PGE1 infusion. Thirteen out of 213 patients (5.6%) had side effects such as excessive hypotension (1%), phlebitis (3%), and unexpected tachycardia (1 %), which were alleviated gradually after discontinuation of PGEI infusion. No dysarrhythmia and further ST segment changes in the electrocardiograms were observed. These findings suggest that PGE1 can be safely used to control arterial blood pressure during surgery in patients having preoperative hypertension and ischemic heart disease.

UR - http://www.scopus.com/inward/record.url?scp=0027451324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027451324&partnerID=8YFLogxK

U2 - 10.1007/s0054030070173

DO - 10.1007/s0054030070173

M3 - Article

AN - SCOPUS:0027451324

VL - 7

SP - 173

EP - 183

JO - Journal of Anesthesia

JF - Journal of Anesthesia

SN - 0913-8668

IS - 2

ER -